Fig. 3

ELISA assay and ROC analysis of CLU or CA19-9 in the bile and serum. A A summary of the patient cohort used for pilot study of CLU. B ELISA analysis of CLU in serum from 40 CCA patients, 40 benign biliary diseases patients, and 40 healthy donors. C ELISA analysis of CLU in bile from 40 CCA patients and 40 benign biliary diseases patients. D A summary of the patient cohort used for the pilot study of CA19-9. E, F ELISA analysis of CA19-9 in the serum and bile from 40 CCA patients and 40 benign biliary diseases patients. G A summary of the patient cohort in cross-validation set. H, I ELISA analysis of bile CLU and serum CA19-9 from 144 CCA patients and 232 non-CCA patients. J The ROC curves of bile CLU, serum CA19-9, and CLU&CA19-9; the blue curve represents CLU, the green curve represents CA19-9, and the red curve represents CLU&CA19-9; the data means AUC (95%CI). K The accuracy (ACC), sensitivity, and specificity of bile CLU, serum CA19-9, and CLU&CA19-9. *p < 0.05, **p < 0.01, ***p < 0.001